- Home
- SW vs DGX Comparison
SW vs DGX Comparison
Compare SW & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SW | DGX |
|---|---|---|
| Founded | 1934 | 1967 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 19.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | SW | DGX |
|---|---|---|
| Price | $42.73 | $189.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $52.00 | ★ $196.69 |
| AVG Volume (30 Days) | ★ 4.7M | 897.8K |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | ★ 3.98% | 1.68% |
| EPS Growth | ★ 109.82 | 14.49 |
| EPS | 1.42 | ★ 8.51 |
| Revenue | ★ $31,138,000,000.00 | $10,850,000,000.00 |
| Revenue This Year | $52.96 | $12.37 |
| Revenue Next Year | $2.73 | $3.54 |
| P/E Ratio | $30.50 | ★ $22.35 |
| Revenue Growth | ★ 89.50 | 13.74 |
| 52 Week Low | $32.73 | $148.70 |
| 52 Week High | $56.05 | $197.55 |
Technical Indicators
Market Signals| Indicator | SW | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 65.88 |
| Support Level | $39.45 | $173.51 |
| Resistance Level | $43.67 | $190.99 |
| Average True Range (ATR) | 1.24 | 3.64 |
| MACD | 0.25 | 1.88 |
| Stochastic Oscillator | 81.47 | 91.65 |
Price Performance
Historical ComparisonAbout SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.